AbbVie jumps on the oncolytics bandwagon, embracing Turnstone in new collaboration
AbbVie has paid for a front row seat on the cancer drug strategy being investigated in the clinic at Turnstone Biologics. The pharma outfit snagged an option to buy Turnstone’s lead therapy combining an oncolytic virus approach and cancer vaccine. And if they dive in, AbbVie expects to line up a shot at a series of tumor types with an option on two more programs that Turnstone will work on.
“This is the largest partnership ever formed in this field,” says Turnstone CEO Sammy Farah, who’s clearly pumped to be aligning his biotech with a prominent player in cancer R&D. “It’s a very significant, very meaningful partnership on many levels.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.